Pharmacogenomics Technology (Theranostics & CDx) Industry Research Report 2023
Highlights
The global Pharmacogenomics Technology (Theranostics & CDx) market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
North American market for Pharmacogenomics Technology (Theranostics & CDx) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
Asia-Pacific market for Pharmacogenomics Technology (Theranostics & CDx) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
The major global companies of Pharmacogenomics Technology (Theranostics & CDx) include Illumina, Roche, Agilent, Abbott, Thermofisher, Qiagen, Guardant Health, MGI Tech Co., Ltd. and Amoydx Biology, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
The global market for Pharmacogenomics Technology (Theranostics & CDx) in Tumor is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Instrument, which accounted for % of the global market of Pharmacogenomics Technology (Theranostics & CDx) in 2022, is expected to reach million US$ by 2029, growing at a revised CAGR of % from 2024 to 2029.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pharmacogenomics Technology (Theranostics & CDx), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacogenomics Technology (Theranostics & CDx).
The Pharmacogenomics Technology (Theranostics & CDx) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Pharmacogenomics Technology (Theranostics & CDx) market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmacogenomics Technology (Theranostics & CDx) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Global markets are presented by Pharmacogenomics Technology (Theranostics & CDx) type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Pharmacogenomics Technology (Theranostics & CDx) are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Pharmacogenomics Technology (Theranostics & CDx) segment by Type
This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Pharmacogenomics Technology (Theranostics & CDx) market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Pharmacogenomics Technology (Theranostics & CDx) market.
Pharmacogenomics Technology (Theranostics & CDx) Segment by Application
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Pharmacogenomics Technology (Theranostics & CDx) market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacogenomics Technology (Theranostics & CDx) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Pharmacogenomics Technology (Theranostics & CDx) and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Pharmacogenomics Technology (Theranostics & CDx) industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacogenomics Technology (Theranostics & CDx).
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Pharmacogenomics Technology (Theranostics & CDx) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
The global Pharmacogenomics Technology (Theranostics & CDx) market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
North American market for Pharmacogenomics Technology (Theranostics & CDx) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
Asia-Pacific market for Pharmacogenomics Technology (Theranostics & CDx) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
The major global companies of Pharmacogenomics Technology (Theranostics & CDx) include Illumina, Roche, Agilent, Abbott, Thermofisher, Qiagen, Guardant Health, MGI Tech Co., Ltd. and Amoydx Biology, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
The global market for Pharmacogenomics Technology (Theranostics & CDx) in Tumor is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Instrument, which accounted for % of the global market of Pharmacogenomics Technology (Theranostics & CDx) in 2022, is expected to reach million US$ by 2029, growing at a revised CAGR of % from 2024 to 2029.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pharmacogenomics Technology (Theranostics & CDx), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacogenomics Technology (Theranostics & CDx).
The Pharmacogenomics Technology (Theranostics & CDx) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Pharmacogenomics Technology (Theranostics & CDx) market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmacogenomics Technology (Theranostics & CDx) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Illumina
- Roche
- Agilent
- Abbott
- Thermofisher
- Qiagen
- Guardant Health
- MGI Tech Co., Ltd.
- Amoydx Biology
- Genomics
Global markets are presented by Pharmacogenomics Technology (Theranostics & CDx) type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Pharmacogenomics Technology (Theranostics & CDx) are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Pharmacogenomics Technology (Theranostics & CDx) segment by Type
- Instrument
- Reagents and Consumables
- Others
This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Pharmacogenomics Technology (Theranostics & CDx) market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Pharmacogenomics Technology (Theranostics & CDx) market.
Pharmacogenomics Technology (Theranostics & CDx) Segment by Application
- Tumor
- Diabetes
- Mental Diseases
- Cardiovascular Diseases
- Others
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Pharmacogenomics Technology (Theranostics & CDx) market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacogenomics Technology (Theranostics & CDx) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Pharmacogenomics Technology (Theranostics & CDx) and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Pharmacogenomics Technology (Theranostics & CDx) industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacogenomics Technology (Theranostics & CDx).
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Pharmacogenomics Technology (Theranostics & CDx) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Pharmacogenomics Technology (Theranostics & CDx) by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Instrument
1.2.3 Reagents and Consumables
1.2.4 Others
2.3 Pharmacogenomics Technology (Theranostics & CDx) by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Tumor
2.3.3 Diabetes
2.3.4 Mental Diseases
2.3.5 Cardiovascular Diseases
2.3.6 Others
2.4 Assumptions and Limitations
3 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS & CDX) BREAKDOWN DATA BY TYPE
3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Type (2018-2023)
3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2023-2028)
4 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS & CDX) BREAKDOWN DATA BY APPLICATION
4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Application (2018-2023)
4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2018-2023)
5 GLOBAL GROWTH TRENDS
5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Perspective (2018-2029)
5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Growth Trends by Region
5.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Region (2018-2023)
5.2.3 Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2024-2029)
5.3 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics
5.3.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends
5.3.2 Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
5.3.3 Pharmacogenomics Technology (Theranostics & CDx) Market Challenges
5.3.4 Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue
6.1.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue (2018-2023)
6.1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2018-2023)
6.2 Global Pharmacogenomics Technology (Theranostics & CDx) Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Pharmacogenomics Technology (Theranostics & CDx) Head office and Area Served
6.4 Global Pharmacogenomics Technology (Theranostics & CDx) Players, Product Type & Application
6.5 Global Pharmacogenomics Technology (Theranostics & CDx) Players, Date of Enter into This Industry
6.6 Global Pharmacogenomics Technology (Theranostics & CDx) Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)
7.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)
7.4 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)
8.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)
8.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)
9.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)
9.4 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 LATIN AMERICA
10.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)
10.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)
10.4 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)
11.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)
11.4 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 PLAYERS PROFILED
11.1 Illumina
11.1.1 Illumina Company Detail
11.1.2 Illumina Business Overview
11.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.1.4 Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.1.5 Illumina Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.2.4 Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.2.5 Roche Recent Development
11.3 Agilent
11.3.1 Agilent Company Detail
11.3.2 Agilent Business Overview
11.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.3.4 Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.3.5 Agilent Recent Development
11.4 Abbott
11.4.1 Abbott Company Detail
11.4.2 Abbott Business Overview
11.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.4.4 Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.4.5 Abbott Recent Development
11.5 Thermofisher
11.5.1 Thermofisher Company Detail
11.5.2 Thermofisher Business Overview
11.5.3 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.5.4 Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.5.5 Thermofisher Recent Development
11.6 Qiagen
11.6.1 Qiagen Company Detail
11.6.2 Qiagen Business Overview
11.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.6.4 Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.6.5 Qiagen Recent Development
11.7 Guardant Health
11.7.1 Guardant Health Company Detail
11.7.2 Guardant Health Business Overview
11.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.7.4 Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.7.5 Guardant Health Recent Development
11.8 MGI Tech Co., Ltd.
11.8.1 MGI Tech Co., Ltd. Company Detail
11.8.2 MGI Tech Co., Ltd. Business Overview
11.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.8.4 MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.8.5 MGI Tech Co., Ltd. Recent Development
11.9 Amoydx Biology
11.9.1 Amoydx Biology Company Detail
11.9.2 Amoydx Biology Business Overview
11.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.9.4 Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.9.5 Amoydx Biology Recent Development
11.10 Genomics
11.10.1 Genomics Company Detail
11.10.2 Genomics Business Overview
11.10.3 Genomics Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.10.4 Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.10.5 Genomics Recent Development
13 REPORT CONCLUSION
14 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Pharmacogenomics Technology (Theranostics & CDx) by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Instrument
1.2.3 Reagents and Consumables
1.2.4 Others
2.3 Pharmacogenomics Technology (Theranostics & CDx) by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Tumor
2.3.3 Diabetes
2.3.4 Mental Diseases
2.3.5 Cardiovascular Diseases
2.3.6 Others
2.4 Assumptions and Limitations
3 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS & CDX) BREAKDOWN DATA BY TYPE
3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Type (2018-2023)
3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2023-2028)
4 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS & CDX) BREAKDOWN DATA BY APPLICATION
4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Application (2018-2023)
4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2018-2023)
5 GLOBAL GROWTH TRENDS
5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Perspective (2018-2029)
5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Growth Trends by Region
5.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Region (2018-2023)
5.2.3 Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2024-2029)
5.3 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics
5.3.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends
5.3.2 Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
5.3.3 Pharmacogenomics Technology (Theranostics & CDx) Market Challenges
5.3.4 Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue
6.1.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue (2018-2023)
6.1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2018-2023)
6.2 Global Pharmacogenomics Technology (Theranostics & CDx) Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Pharmacogenomics Technology (Theranostics & CDx) Head office and Area Served
6.4 Global Pharmacogenomics Technology (Theranostics & CDx) Players, Product Type & Application
6.5 Global Pharmacogenomics Technology (Theranostics & CDx) Players, Date of Enter into This Industry
6.6 Global Pharmacogenomics Technology (Theranostics & CDx) Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)
7.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)
7.4 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)
8.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)
8.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)
9.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)
9.4 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 LATIN AMERICA
10.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)
10.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)
10.4 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)
11.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)
11.4 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 PLAYERS PROFILED
11.1 Illumina
11.1.1 Illumina Company Detail
11.1.2 Illumina Business Overview
11.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.1.4 Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.1.5 Illumina Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.2.4 Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.2.5 Roche Recent Development
11.3 Agilent
11.3.1 Agilent Company Detail
11.3.2 Agilent Business Overview
11.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.3.4 Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.3.5 Agilent Recent Development
11.4 Abbott
11.4.1 Abbott Company Detail
11.4.2 Abbott Business Overview
11.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.4.4 Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.4.5 Abbott Recent Development
11.5 Thermofisher
11.5.1 Thermofisher Company Detail
11.5.2 Thermofisher Business Overview
11.5.3 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.5.4 Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.5.5 Thermofisher Recent Development
11.6 Qiagen
11.6.1 Qiagen Company Detail
11.6.2 Qiagen Business Overview
11.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.6.4 Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.6.5 Qiagen Recent Development
11.7 Guardant Health
11.7.1 Guardant Health Company Detail
11.7.2 Guardant Health Business Overview
11.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.7.4 Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.7.5 Guardant Health Recent Development
11.8 MGI Tech Co., Ltd.
11.8.1 MGI Tech Co., Ltd. Company Detail
11.8.2 MGI Tech Co., Ltd. Business Overview
11.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.8.4 MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.8.5 MGI Tech Co., Ltd. Recent Development
11.9 Amoydx Biology
11.9.1 Amoydx Biology Company Detail
11.9.2 Amoydx Biology Business Overview
11.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.9.4 Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.9.5 Amoydx Biology Recent Development
11.10 Genomics
11.10.1 Genomics Company Detail
11.10.2 Genomics Business Overview
11.10.3 Genomics Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.10.4 Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.10.5 Genomics Recent Development
13 REPORT CONCLUSION
14 DISCLAIMER
LIST OF TABLES
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2018-2023)
Table 7. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2024-2029)
Table 9. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2018-2023)
Table 11. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2024-2029)
Table 13. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2018-2023)
Table 16. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2024-2029)
Table 18. Pharmacogenomics Technology (Theranostics & CDx) Market Trends
Table 19. Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
Table 20. Pharmacogenomics Technology (Theranostics & CDx) Market Challenges
Table 21. Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
Table 22. Global Top Pharmacogenomics Technology (Theranostics & CDx) Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Pharmacogenomics Technology (Theranostics & CDx) Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Pharmacogenomics Technology (Theranostics & CDx), Headquarters and Area Served
Table 26. Global Pharmacogenomics Technology (Theranostics & CDx) Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Pharmacogenomics Technology (Theranostics & CDx) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US$ Million)
Table 45. Illumina Company Detail
Table 46. Illumina Business Overview
Table 47. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product
Table 48. Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 49. Illumina Recent Development
Table 50. Roche Company Detail
Table 51. Roche Business Overview
Table 52. Roche Pharmacogenomics Technology (Theranostics & CDx) Product
Table 53. Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 54. Roche Recent Development
Table 55. Agilent Company Detail
Table 56. Agilent Business Overview
Table 57. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product
Table 58. Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 59. Agilent Recent Development
Table 60. Abbott Company Detail
Table 61. Abbott Business Overview
Table 62. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product
Table 63. Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 64. Abbott Recent Development
Table 65. Thermofisher Company Detail
Table 66. Thermofisher Business Overview
Table 67. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Product
Table 68. Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 69. Thermofisher Recent Development
Table 70. Qiagen Company Detail
Table 71. Qiagen Business Overview
Table 72. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product
Table 73. Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 74. Qiagen Recent Development
Table 75. Guardant Health Company Detail
Table 76. Guardant Health Business Overview
Table 77. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product
Table 78. Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 79. Guardant Health Recent Development
Table 80. MGI Tech Co., Ltd. Company Detail
Table 81. MGI Tech Co., Ltd. Business Overview
Table 82. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Product
Table 83. MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 84. MGI Tech Co., Ltd. Recent Development
Table 85. Amoydx Biology Company Detail
Table 86. Amoydx Biology Business Overview
Table 87. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Product
Table 88. Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 89. Amoydx Biology Recent Development
Table 90. Genomics Company Detail
Table 91. Genomics Business Overview
Table 92. Genomics Pharmacogenomics Technology (Theranostics & CDx) Product
Table 93. Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 94. Genomics Recent Development
Table 95. Illumina Company Information
Table 96. Illumina Business Overview
Table 97. Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 98. Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 99. Illumina Recent Development
Table 100. Roche Company Information
Table 101. Roche Business Overview
Table 102. Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 103. Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 104. Roche Recent Development
Table 105. Agilent Company Information
Table 106. Agilent Business Overview
Table 107. Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 108. Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 109. Agilent Recent Development
Table 110. Abbott Company Information
Table 111. Abbott Business Overview
Table 112. Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 113. Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 114. Abbott Recent Development
Table 115. Thermofisher Company Information
Table 116. Thermofisher Business Overview
Table 117. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 118. Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 119. Thermofisher Recent Development
Table 120. Qiagen Company Information
Table 121. Qiagen Business Overview
Table 122. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 123. Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 124. Qiagen Recent Development
Table 125. Guardant Health Company Information
Table 126. Guardant Health Business Overview
Table 127. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 128. Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 129. Guardant Health Recent Development
Table 130. MGI Tech Co., Ltd. Company Information
Table 131. MGI Tech Co., Ltd. Business Overview
Table 132. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 133. MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 134. MGI Tech Co., Ltd. Recent Development
Table 135. Amoydx Biology Company Information
Table 136. Amoydx Biology Business Overview
Table 137. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 138. Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 139. Amoydx Biology Recent Development
Table 140. Genomics Company Information
Table 141. Genomics Business Overview
Table 142. Genomics Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 143. Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2018-2023)
Table 7. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2024-2029)
Table 9. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2018-2023)
Table 11. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2024-2029)
Table 13. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2018-2023)
Table 16. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2024-2029)
Table 18. Pharmacogenomics Technology (Theranostics & CDx) Market Trends
Table 19. Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
Table 20. Pharmacogenomics Technology (Theranostics & CDx) Market Challenges
Table 21. Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
Table 22. Global Top Pharmacogenomics Technology (Theranostics & CDx) Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Pharmacogenomics Technology (Theranostics & CDx) Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Pharmacogenomics Technology (Theranostics & CDx), Headquarters and Area Served
Table 26. Global Pharmacogenomics Technology (Theranostics & CDx) Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Pharmacogenomics Technology (Theranostics & CDx) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US$ Million)
Table 45. Illumina Company Detail
Table 46. Illumina Business Overview
Table 47. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product
Table 48. Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 49. Illumina Recent Development
Table 50. Roche Company Detail
Table 51. Roche Business Overview
Table 52. Roche Pharmacogenomics Technology (Theranostics & CDx) Product
Table 53. Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 54. Roche Recent Development
Table 55. Agilent Company Detail
Table 56. Agilent Business Overview
Table 57. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product
Table 58. Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 59. Agilent Recent Development
Table 60. Abbott Company Detail
Table 61. Abbott Business Overview
Table 62. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product
Table 63. Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 64. Abbott Recent Development
Table 65. Thermofisher Company Detail
Table 66. Thermofisher Business Overview
Table 67. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Product
Table 68. Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 69. Thermofisher Recent Development
Table 70. Qiagen Company Detail
Table 71. Qiagen Business Overview
Table 72. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product
Table 73. Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 74. Qiagen Recent Development
Table 75. Guardant Health Company Detail
Table 76. Guardant Health Business Overview
Table 77. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product
Table 78. Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 79. Guardant Health Recent Development
Table 80. MGI Tech Co., Ltd. Company Detail
Table 81. MGI Tech Co., Ltd. Business Overview
Table 82. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Product
Table 83. MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 84. MGI Tech Co., Ltd. Recent Development
Table 85. Amoydx Biology Company Detail
Table 86. Amoydx Biology Business Overview
Table 87. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Product
Table 88. Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 89. Amoydx Biology Recent Development
Table 90. Genomics Company Detail
Table 91. Genomics Business Overview
Table 92. Genomics Pharmacogenomics Technology (Theranostics & CDx) Product
Table 93. Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 94. Genomics Recent Development
Table 95. Illumina Company Information
Table 96. Illumina Business Overview
Table 97. Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 98. Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 99. Illumina Recent Development
Table 100. Roche Company Information
Table 101. Roche Business Overview
Table 102. Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 103. Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 104. Roche Recent Development
Table 105. Agilent Company Information
Table 106. Agilent Business Overview
Table 107. Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 108. Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 109. Agilent Recent Development
Table 110. Abbott Company Information
Table 111. Abbott Business Overview
Table 112. Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 113. Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 114. Abbott Recent Development
Table 115. Thermofisher Company Information
Table 116. Thermofisher Business Overview
Table 117. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 118. Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 119. Thermofisher Recent Development
Table 120. Qiagen Company Information
Table 121. Qiagen Business Overview
Table 122. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 123. Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 124. Qiagen Recent Development
Table 125. Guardant Health Company Information
Table 126. Guardant Health Business Overview
Table 127. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 128. Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 129. Guardant Health Recent Development
Table 130. MGI Tech Co., Ltd. Company Information
Table 131. MGI Tech Co., Ltd. Business Overview
Table 132. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 133. MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 134. MGI Tech Co., Ltd. Recent Development
Table 135. Amoydx Biology Company Information
Table 136. Amoydx Biology Business Overview
Table 137. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 138. Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
Table 139. Amoydx Biology Recent Development
Table 140. Genomics Company Information
Table 141. Genomics Business Overview
Table 142. Genomics Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million)
Table 143. Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US$ Million) Portfolio
